Gene Biotherapeutics, Inc. (CRXM)

USD 0.0

(9900.0%)

Long Term Debt Summary of Gene Biotherapeutics, Inc.

  • Gene Biotherapeutics, Inc.'s latest annual long term debt in 2022 was - USD , down 0.0% from previous year.
  • Gene Biotherapeutics, Inc.'s latest quarterly long term debt in 2022 FY was - USD , down 0.0% from previous quarter.
  • Gene Biotherapeutics, Inc. reported annual long term debt of - USD in 2021, down -100.0% from previous year.
  • Gene Biotherapeutics, Inc. reported annual long term debt of 107.89 Thousand USD in 2020, down -11.72% from previous year.
  • Gene Biotherapeutics, Inc. reported quarterly long term debt of - USD for 2021 FY, down -100.0% from previous quarter.
  • Gene Biotherapeutics, Inc. reported quarterly long term debt of 107.89 Thousand USD for 2020 FY, down -11.72% from previous quarter.

Annual Long Term Debt Chart of Gene Biotherapeutics, Inc. (2022 - 1995)

Historical Annual Long Term Debt of Gene Biotherapeutics, Inc. (2022 - 1995)

Year Long Term Debt Long Term Debt Growth
2022 - USD 0.0%
2021 - USD -100.0%
2020 107.89 Thousand USD -11.72%
2019 122.2 Thousand USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%
2014 - USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%
2010 - USD 0.0%
2009 - USD 0.0%
2008 - USD -100.0%
2007 3.24 Million USD 0.0%
2006 - USD 0.0%
2005 - USD 0.0%
2004 - USD 0.0%
2003 - USD 0.0%
2002 - USD 0.0%
2001 - USD 0.0%
2000 - USD 0.0%
1999 - USD 0.0%
1998 - USD 0.0%
1997 - USD -100.0%
1996 5.07 Million USD -0.0%
1995 5.07 Million USD 0.0%

Peer Long Term Debt Comparison of Gene Biotherapeutics, Inc.

Name Long Term Debt Long Term Debt Difference
America Great Health 1.12 Million USD 100.0%
Evolutionary Genomics, Inc. 3.74 Million USD 100.0%
Innovation1 Biotech Inc. 218.99 Thousand USD 100.0%
Point of Care Nano-Technology, Inc. - USD NaN%
Vicapsys Life Sciences, Inc. - USD NaN%